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Abstract 
Aberrant DNA hypermethylation is a hallmark of cancer although the underlying 
molecular mechanisms are still poorly understood. To study the possible role of 5-
hydroxymethylcytosine (5hmC) in this process we analyzed the global and locus-
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specific genome-wide levels of 5hmC and 5mC in human primary samples from 12 
non-tumoral brains and 53 gliomas. We found that the levels of 5hmC identified in non-
tumoral samples were significantly reduced in gliomas. Strikingly, hypo-
hydroxymethylation at 4,627 (9.3%) CpG sites was associated with aberrant DNA 
hypermethylation and was strongly enriched in CpG island (CGI) shores. The DNA 
regions containing these CpG sites were enriched in H3K4me2 and presented a different 
genuine chromatin signature to that characteristic of the genes classically aberrantly 
hypermethylated in cancer. As this 5mC gain is inversely correlated with loss of 5hmC 
and has not been identified with classical sodium bisulfite-based technologies, we 
conclude that our data identifies a novel 5hmC-dependent type of aberrant DNA 
hypermethylation in glioma. 
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Introduction 
DNA methylation at the fifth position of cytosine (5mC) has been one of the most 
studied epigenetic modifications in mammals to date. 5mC is involved in the regulation 
of multiple physiological and pathological processes, including cancer, and when 
located at gene promoters, it is usually linked to transcriptional repression.  
As distinctive features of tumorigenesis, local DNA hypermethylation and global 
hypomethylation have been attributed to changes in 5mC levels (1, 2). However, the 
discovery a few years ago, of 5-hydroxymethylcytosine (5hmC), a new epigenetic mark 
resulting from 5mC oxidation, is reshaping our view of the cancer epigenome (3, 4). 
This 5mC to 5hmC conversion in mammals is mediated by ten-eleven translocation 
proteins (TET1, TET2, and TET3), a family of α-ketoglutarate (αKG) and Fe(II)-
dependent dioxygenases (4, 5). Global levels of 5hmC in the genome fluctuate 
considerably according to tissue type, and are consistently around 10-fold lower than 
those of 5mC, though it is interesting that the highest levels of both marks are found in 
brain (6-11). 
Several studies have shown that 5hmC is an intermediate of DNA demethylation (7, 12, 
13), and that it is also associated with cancer (14-18). In this same vein, loss of 5hmC 
has been reported across a wide range of human cancers including melanoma, glioma, 
breast, colon, gastric, kidney, liver, lung, pancr atic, and prostate cancers (9, 14, 18-22). 
Although none of these studies actually demonstrate that changes in 5hmC are directly 
affecting cancer biology independent of its role in DNA demethylation, other studies 
identifying 5hmC-specific protein binders suggest that this epigenetic mark might have 
its own biological role (23, 24). The fact that there are now methods available that 
distinguish 5mC and 5hmC positions at single-base resolution within the genome 
prompted us to reassess the role of DNA methylation status in tumorigenesis from a 
5hmC perspective. The method used here allowed us to describe global and genome-
wide locus-specific 5mC and 5hmC patterns in brain samples, to identify a specific 
chromatin signature associated with changes of these epigenetic marks in glioma and, 
most importantly, to describe a novel non-canonical type of aberrant DNA 
hypermethylation. 
 
Results 
Global changes of 5mC and 5hmC in cancer 
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To evaluate the role of 5hmC in the changes of DNA methylation observed in glioma, 
we first analyzed the levels of 5hmC and 5mC at DNA repeats in 11 normal and 50 
tumor samples. We used oxidative bisulfite conversion (oxBS) of DNA to discriminate 
between 5mC and 5hmC (see Methods) and bisulfite pyrosequencing was used to 
determine the level of both epigenetic modifications in 4 different types of repeated 
DNA: the retrotransposons LINE-1 and AluYb8, and the pericentromeric tandem 
repeats Sat-alpha and NBL-2 (25). These 4 DNA regions contain most of the genomic 
methylation and, consequently, global DNA methylation level is highly dependent on 
their 5mC content (26). As expected, 5mC levels at repeated DNA in healthy tissue 
were high but were reduced in tumor samples, a change which was statistically 
significant in LINE-1 and Sat-alpha (linear model, p<0.001) (Fig. 1a). In contrast, 
levels of 5hmC at repeated DNA in healthy tissue were low, while tumoral tissue 
showed even lower levels of 5hmC in the same DNA regions, although this was only 
statistically significant in LINE-1 (linear model, p< 0.05). (Fig. 1b). 
 
5mC and 5hmC profiling in brain tissue 
As changes in 5hmC at repeated DNA were not able to explain the global loss of this 
epigenetic mark previously observed by mass spectrometry (14, 20, 27, 28), we 
hypothesized that these changes primarily occur at single copy sequences. To 
investigate this possibility in more detail, we first used 450K Infinium methylation 
arrays to determine the level and genomic distribution of 5mC and 5hmC in 5 healthy 
brain tissue samples. A preliminary examination of the data revealed that the beta values 
of the oxidized samples (true 5mC) were lower than their non-oxidized counterparts 
(5mC+5hmC) (Wilcoxon rank sum test; p<0.001; W=2.34e13) (Fig. 2a). Specifically, 
111,633 hydroxymethylated CpG sites (5hmC sites) distributed throughout the whole 
genome were identified, irrespective of the chromosome analyzed (Fig. 2a, and 
Supplementary Table 1). 
To further validate the consistency of our results we compared our data with published 
data for 5hmC in human normal brain (29) obtained by Tet-Assisted Bisulfite 
Sequencing (TAB-Seq), an alternative technique that directly measures the 5hmC rather 
than inferring it, and we found that more than 75% of the 5hmC-enriched CpG sites 
identified in our study overlapped with 5hmC-enriched CpG sites analyzed by the TAB-
Seq (Supplementary Fig. S1). 
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The analysis of the genomic distribution of the 5hmC sites showed that 
hydroxymethylation is enriched at the low CpG-density regions interrogated by the 
array (Wilcoxon non-parametric test; p<0.001, D=-0.29, and p<0.001, D=-0.5, 
respectively) (Fig. 2b). Consequently, the 5hmC sites were enriched in non-CpG islands 
(non-CGI) (chi-square test; p<0.001; OR=1.93, and p<0.001, OR=3.45, respectively) 
and infrequent in CGIs (chi-square test; p<0.001, OR=0.14, and p<0.001, OR=0.13) 
(Fig. 2c). With respect to genes, 5hmC sites were enriched in introns (chi-square test; 
p<0.001, OR=1.82, and p<0.001, OR=1.76, respectively), but were less frequent than 
expected in gene promoters (chi-square test; p<0.001, OR=0.58, and p<0.001, OR=0.6) 
(Fig. 2d).  
To identify possible chromatin marks associated with 5hmC sites, we compared these 
CpG sites with previ usly published data on a range of histone modifications and 
chromatin modifiers in 10 different cell types (see Methods) (Fig. 2e). This approach 
identified statistically significant associations (Fisher´s exact test; p<0.05) between the 
5hmC sites in brain and the active histone marks H3K4me1, H3K36me3, and 
H4K20me1 (Fig. 2e). A similar framework was used to test for the enrichment of our 
selected probes over the computer-generated chromatin segmentation states from the 
ENCODE ChromHMM project (see Methods). In total, fifteen states were used to 
segment the genome, and these were then grouped and colored to highlight predicted 
functional elements. This approach showed that the hmC sites were significantly 
enriched in states associated with enhancers and transcription (Fisher´s exact test; 
p<0.05) (Fig. 2f). These associations were further corroborated by using available 
ChIP-seq tracks from epigenomes of 8 brain cell types obtained from the NIH Roadmap 
Epigenome consortia (30) (Fisher´s exact test; p<0.05) (Supplementary Figure S2). 
 
Locus-specific alterations of 5hmC in glioma 
To identify differentially hydroxymethylated CpG sites (d5hmC) at single copy 
sequences in cancer, we used 450K methylation arrays to analyze 9 primary tumors 
obtained from patients with glioma (see Methods). A total of 49,601 CpG sites that 
were hypo-hydroxymethylated were identified in gliomas, but almost no hyper-
hydroxymethylated sites were found (see Methods) (Fig. 3a and Supplementary Table 
2). To validate the results obtained with the methylation arrays with an alternative 
technique nondependent on the oxidative bisulfite conversion of DNA, we randomly 
selected five of the 100 most variable sequences previously identified and analyzed their 
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5hmC status using a hydroxymethylated DNA Immunoprecipitation (hMeDIP) Kit 
(Epigentek; see Methods) in 5 brain samples and 5 gliomas. The results corroborated 
the massive loss of 5-hydroxymethylation in glioma in all the candidate sequences 
(Mann Whitney test; p<0.05) (Supplementary Figure S3). 
Hierarchical clustering using the differentially hydroxymethylated CpG sites showed 
the correct classification of normal and tumor samples (Fig. 3b). The analysis of the 
genomic distribution of the hypo-hydroxymethylated CpG sites in gliomas showed an 
enrichment at low CpG density regions (Wilcoxon rank sum test, p<0.001, D=-0.41), 
and consequently at non-CpG islands (chi-squared test, p<0.001, OR=2.53) (Fig. 3c). 
With respect to gene location, hypo-hydroxymethylation was more frequent in introns 
(chi-squared test, p<0.001, OR=1.77) (Fig. 3c). 
To identify possible chromatin signatures associated with DNA hypo-
hydroxymethylation in gliomas, we compared our list of hypo-hydroxymethylated CpG 
sites with previously published data on a range of histone modifications and chromatin 
modifiers in 10 different cell types (see Methods) (Fig. 3d). Interestingly, this approach 
showed an enrichment of hypo-hydroxymethylation at chromatin regions marked with 
the activating histone PTMs H3K4me1, H3K36me3, H4K20me1 and H3K79me2 
(Fisher's exact test, p<0.05) (Fig. 3d), but not with the repressive histone modification 
H3K27me3, which has been previously shown to be associated with aberrant DNA 
hypermethylation in cancer (31, 32) (Fig. 3d). A similar framework was used to test for 
the enrichment of our selected probes over the computer-generated chromatin 
segmentation states from the ENCODE ChromHMM project. Using this approach, we 
found that hypohydroxymethylated CpG sites were significantly associated with 
transcription regulation and enhancers (Fisher’s exact test; p < 0.05) (Fig. 3e). These 
associations were further corroborated using available ChIP-seq tracks from the 
epigenomes of 8 types of brain cell obtained from the NIH Roadmap Epigenome 
consortia (30) (Fisher´s exact test; p<0.05) (Supplementary Figure S4). 
 
DNA hypo-hydroxymethylation identifies a novel type of non-canonical aberrant 
DNA hyper-methylation in glioma 
To study the relationship between changes in 5mC and 5hmC in glioma, we first 
identified aberrantly methylated CpG (d5mC) sites. The comparison of the methylation 
data between tumoral and control samples (see Methods) identified 2,727 hypo- and 
12,050 hyper-methylated CpG sites in gliomas (Supplementary Tables 3 and 4). Next, 
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we compared these d5mC sites with the previously identified hypo-hydroxymethylated 
CpG sites (Fig. 3a, Supplementary Table 2). This approach showed that 4,627 
(38.4%) of the CpG sites aberrantly hypermethylated in gliomas also lost 5hmC (Fig. 
4a, Supplementary Table 5). Interestingly, those CpG sites were those that showed the 
highest values of 5hmC in normal tissue (Supplementary Fig. S5) (Wilcoxon rank sum 
test, p< 0.001).  
To verify that these hypermethylated CpG sites that also lose 5hmC in gliomas 
(hyper5mC-hypo5hmC) had not been identified in previous studies, owing to no 
distinction being made between 5mC and 5hmC, we compared the DNA methylation 
values of our samples with those of gliomas obtained from the same type of methylation 
array available in TCGA (33). We observed that not separating 5mC and the 5hmC 
resulted in many false negatives for hypermethylation in gliomas since the gain of 5mC 
in tumors was masked by the high levels of 5hmC in normal brain (Supplementary 
Fig. S6a). However, irrespective of the issue of separating or not 5mC and 5hmC, 
similar results were found when we performed the same comparisons using 
hypermethylated CpG sites that showed no changes in 5hmC in gliomas, since, in this 
case, these CpGs showed very low levels of 5hmC in normal brain (Supplementary 
Fig. S6b). 
To investigate, at a functional genomic level, the characteristics of these two classes of 
aberrantly hypermethylated CpG sites in gliomas we first analyzed their genomic 
distribution in relation to density of CpG sites and we found that the hypermethylated 
CpG sites that lose 5hmC (hyper5mC-hypo5hmC) were enriched in low density CpG 
regions (Wilcoxon rank sum test, p<0.001, D=-0.11) as compared with the 
hypermethylated CpG sites that showed no changes in 5hmC (hyper5mC) (Wilcoxon 
rank sum test, p<0.001, D=-0.23) (Fig. 4b, Supplementary Tables 5 and 6). 
Furthermore, hyper5mC-hypo5hmC sites were strongly depleted from CGIs (chi-
squared test, p<0.001, OR=0.42) and enriched in CGI shores (chi-squared test, p<0.001, 
OR=2.03) (Fig. 4b). Hierarchical clustering using the differentially methylated CpG 
sites showed that the hyper5mC-hypo5hmC sites were slightly more methylated in 
control brain samples than the hyper5mC sites, and that they were more uniformly 
hypermethylated in glioma (Fig. 4c). To further corroborate our results, we took 
advantage of recently published data on the whole-genome bisulfite sequencing 
(WGBS), albeit data was from one glioblastoma patient only (34). We found that, in 
addition to a large percentage of CpGs (n: 4,051; 88%) showing the same patterns of 
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change as in our methylation arrays, the WGBS analysis identified more than 106 new 
hyper5mC-hypo5hmC sites, thus confirming that this is a frequent event in glioma 
(Supplementary Fig. S7). 
Next, to identify possible chromatin signatures associated with the two classes of 
aberrantly hypermethylated CpG sites in gliomas, we compared our data with 
previously published data on a range of histone modifications and chromatin modifiers 
in 10 different cell types (see Methods) (Fig. 5a). This approach confirmed the 
association between hyper5mC and the repressive histone marks H3K9me3 and 
H3K27me3 (Fisher's exact test, p<0.05) (31, 32, 35). The hyper5mC-hypo5hmC sites 
showed a completely different chromatin signature, with enrichment in the activating 
histone PTMs H3K4me1, H3K36me3, H3K79me2 and H4K20me1 (Fisher's exact test, 
p<0.05) (Fig. 5a). Notably, as compared with the chromatin signature of the whole set 
of hypo-hydroxymethylated CpGs in glioma, these CpG sites were particularly enriched 
at the H3K4me2 histone mark (Fisher's exact test, p<0.001, OR in [1.19, 1.78] for all 
cell lines in the Broad Histone project) (Fig. 5b). 
These results indicate that the hyper5mC sites behave like the aberrantly 
hypermethylated canonical CpG sites in cancer (i.e., enriched in CGIs and repressive 
histone marks), whilst the hyper5mC-hypo5hmC sites represent a novel and 
functionally different non-canonical type of aberrantly methylated DNA sequence in 
glioma (Fig. 5a, 5b, Supplementary Tables 5 and 6). In support of this notion, 
experiments focused on the computational prediction of functional elements confirmed 
the enrichment of canonical aberrant hypermethylation in promoters and repressed 
sequences and revealed a completely different pattern for non-canonical 
hypermethylation, one which is more closely associated with enhancers and 
transcriptional regulation (Fisher’s exact test; p < 0.05) (Supplementary Fig. S8). 
These associations were also corroborated by using available ChIP-seq tracks from 
epigenomes of 8 types of brain cell obtained from the NIH Roadmap Epigenome 
consortia (30) (Fisher´s exact test; p<0.05) (Supplementary Figure S9). 
 
Distinct functional role of canonical and non-canonical aberrant hypermethylation in 
glioma 
To identify possible differences between the functional role of canonical and non-
canonical aberrant DNA hypermethylation in glioma we first ascribed CpG sites to 
specific genes and then used HOMER to carry out gene ontology analyses of each 
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group of genes (see methods). Using this approach, we identified 1,921 genes 
displaying canonical hypermethylation, 2,042 displaying non-canonical 
hypermethylation and 938 displaying both types of aberrant hypermethylation (Fig. 6a, 
Supplementary Tables 7, 8 and 9). As expected, GO analyses showed an enrichment 
of development and differentiation processes in canonical genes (36) (Fig. 6a, 
Supplementary Table 10). In contrast, non-canonical genes were enriched in cell 
signaling and protein processing pathways (Fig. 6a, Supplementary Table 11). 
To further investigate the functional role of canonical and non-canonical 
hypermethylation in cancer, we compared our methylation data with previously 
published gene expression data in the same type of tumor (see Methods). Results 
showed that 681 (23.8%) of the canonical and 585 (19.6%) of the non-canonical 
aberrantly hypermethylated genes were repressed in gliomas (Fig. 6b). 
Genomic distribution analysis of both types of aberrant hypermethylation confirmed the 
enrichment of canonical hypermethylation in exons (chi-squared test, p<0.001, 
OR=1.79 for general exons, OR=2.01 for first exons), while non-canonical 
hypermethylation was more frequent in introns (chi-squared test, p<0.001, OR=1.7) 
(Fig. 6c). The genes frequently downregulated in glioma, SLC14A and the SMAD7, 
represent two bona fide examples of this pattern of non-canonical aberrant 
hypermethylation (Fig. 6d, Supplementary Fig. S10). 
Taken as a whole, these results indicate that both types of aberrant hypermethylation 
have a similar effect on gene expression, but that they affect different types of genes and 
gene regions. 
 
 
Discussion 
During recent decades, it has largely been accepted that aberrant genomic DNA 
methylation is a hallmark of cancer (1, 2) and the best-known DNA methylation 
alterations in tumors were the aberrant hypermethylation of CpG island promoters, and 
global DNA hypomethylation. In both cases, the alterations were mostly attributed to 
changes in the overall content and genomic distribution of 5mC (1, 2). 
The vast majority of studies on DNA methylation and cancer have been based on the 
sodium bisulfite modification of the genomic DNA, a chemical reaction that allows C 
and 5mC to be distinguished by polymerase chain reaction (37). However, this approach 
cannot distinguish between 5mC and 5-hydroxymethylcytosine (5hmC), the latter being 
a chemical modification of the cytosine first identified in bacteriophages in 1952 (38), 
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and which has recently been found to be quite abundant in specific mammalian tissue 
(3). 5hmC is synthesized from 5mC by the Ten-eleven Translocation (Tet) Enzymes, a 
family of proteins that can also catalyze the successive conversion of 5hmC to 5-
formylcytosine and then to 5-carboxylcytosine, both of which can be transformed to 
unmodified C (39). Although 5hmC was originally described as simply a demethylation 
intermediate of C (7, 12, 13), recent data suggest that this may be an epigenetic mark in 
its own right (40, 41). Thus, as most previous studies did not distinguish between 5mC 
and 5hmC, and it appears that DNA hydroxymethylation might play a specific role in 
cancer, in this work we aimed to re-evaluate changes in DNA methylation in cancer, 
paying special attention to the specific contribution of 5hmC. 
To identify the DNA regions affected by hydroxymethylation changes in cancer, we 
first focused on four types of repeated DNA (LINE1, Sat-alpha, NBL2 and AluYb8). 
Among them, the LINE1 epeat is of particular interest because it contains almost 20% 
of the genomic 5mC, and it has been proposed to be a surrogate of global DNA 
methylation (26). Our results confirmed that tumors lose 5mC at repeated DNA (42). 
However, the level of 5hmC at repeated DNA in healthy samples was very low and no 
significant differences were observed compared to tumors, which indicates that the 
global DNA hypo-hydroxymethylation previously observed in cancer (14, 20, 27, 28, 
43) does not principally occur at repeated DNA. As changes in 5hmC at repeated DNA 
could not explain the global differences previously observed by mass spectrometry (14, 
20, 27, 28), we decided to study the possible contr bution of single copy sequences. 
Genome-wide profiling of 5mC and 5hmC of healthy tissue has identified more than 
100,000 CpG sites frequently hydroxymethylated in brain, providing evidence that the 
level of this epigenetic mark is very abundant in this tissue (3, 7-11). Moreover, 5hmC 
was enriched in specific regions, i.e. those with low CpG density and in introns, 
indicating that 5hmC is not simply a demethylation intermediate (7, 12, 13). 
Interestingly, 5hmC co-localized in regions marked with the activating histone PTM 
H3K4me1. This histone mark has been previously associated with gene enhancers (44, 
45), which suggests that DNA hydroxymethylation might play a role in gene regulation 
in trans. Moreover, we have recently found an association between H3K4me1 and DNA 
hypomethylation during aging in stem and differentiated cells (46), which may 
represent an interesting link between aging and cancer at these genomic regions.  
The cell type(s) from which glioblastomas originate is not well understood at this 
moment in time, although there is some evidence that they might be neuronal stem cells 
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or a glial precursor (47, 48). In our study, normal brain cells were obtained from the 
frontal cortex, which principally comprises neural and glial cells, thus we cannot rule 
out some differences found in our analysis possibly reflecting differences between 
normal cell types. That said, the great number of hypo-hydroxymethylated single CpG 
sites in glioma could explain the global differences previously observed by mass 
spectrometry (14, 20, 27, 28) and suggests that, in contrast to 5mC, most DNA hypo-
hydroxymethylation in brain tumors occurs at single copy sequences.  
The behavior of 5hmC led us to next identify two types of CpG sites aberrantly 
hypermethylated in glioma: i. aberrantly hypermethylated CpG sites that showed no 
changes in 5hmC; and ii. hypermethylated CpG sites that lose 5hmC. This negative 
correlation between changes in 5mC and in 5hmC agrees with that previously found in 
cancer differentially methylated regions (c-DMRs) of both liver and lung tumors (49).  
The former sites display similar chromatin signatures to previously described genes 
aberrantly hypermethylated in cancer (i.e. enrichment in the repressive histone marks 
H3K9me3 and H3K27me3) (31, 32, 35). In contrast, the latter type of aberrantly 
hypermethylated CpG sites were enriched in the activating histone PTMs H3K4me1, 
H3K36me3, H3K79me2, H4K20me1 and H3K4me2. As these CpG sites present a 
genuine chromatin signature which is different to the repressive chromatin signature of 
the classical genes aberrantly hypermethylated in cancer (31, 32, 35), we conclude that 
they represent a novel 5hmC-dependent non-canonical class of aberrant DNA 
hypermethylation in glioma (Fig. 7). As this gain in 5mC is inversely correlated with 
loss of 5hmC, it was not possible to identify this significant alteration in previous 
studies using the classical sodium bisulfite-based technologies, since they are not able to 
distinguish between the two chemical modifications. 
Aberrant DNA hypermethylation in cancer was discovered more than 30 years ago, but 
the underlying molecular mechanisms are still poorly understood. For example, it has 
been proposed that genes enriched in bivalent histone modifications (H3K4me3 and 
H3K27me3) and polycomb group proteins during embryo development are prone to 
become aberrantly hypermethylated in cancer (31, 32, 35) but the molecular basis of 
this is unknown. Our data suggest that tumor cells might in fact acquire aberrant DNA 
methylation through various different pathways. Moreover, in the case of the non-
canonical hypermethylation, the previous loss of 5hmC suggests that aberrant 
hypermethylation at these DNA regions could be due to an attempt by the cell to reverse 
or repair the loss of 5hmC at functionally sensible loci. This possibility is supported by 
Page 12 of 37Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12 
 
the fact that the non-canonical aberrant hypermethylation described here seems to play 
an important role in gene regulation. Intriguingly, 5hmC at gene promoters has also 
been proposed to protect from aberrant hypermethylation in colorectal cancer (28). 
Thus, although it seems that 5hmC plays an important role in the regulation of the DNA 
methylation changes in cancer, more research is needed to fully understand its role. 
The non-canonical aberrant hypermethylation described here seems to have a similar 
overall effect on gene expression as classical canonical hypermethylation, although the 
type of genes and the genomic regions affected are very different. Previous research has 
shown that the repression of developmental genes affected by canonical aberrant 
hypermethylation promotes tumorigenesis (36). However, the possible functional role of 
disruption of cell signaling and protein processing pathways affected by the non-
canonical hypermethylation described in this study remains to be elucidated. Future 
research is thus needed to address this issue, and to determine whether the two types of 
aberrant DNA hypermethylation have distinct functional roles in cancer.  
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Methods 
Normal samples and primary tumors  
Brain samples analyzed in this study were collected at the Hospital Universitario 
Central de Asturias (HUCA), the Hospital Virgen de la Salud, Toledo, and the Hospital 
Universitario Puerta de Hierro, Madrid. The samples studied comprised 12 normal 
brains and 53 glioblastomas. The study was approved by the Clinical Research Ethics 
Committee and all the individuals involved provided written informed consent. 
 
Pyrosequencing assays 
5mC and 5hmC patterns at repetitive sequences (LINE1, AluYb8, Sat-alpha and NBL2) 
were analyzed by pyrosequencing using previously described primers (25). To calculate 
5hmC levels, each sample was analyzed using two methods performed in parallel; an 
oxidative bisulfite conversion (oxBS) and a bisulfite-only conversion (BS), in 
accordance with the TrueMethyl® Array Kit User Guide (CEGX, Version 2) with some 
modifications. Briefly, DNA samples were cleaned using Agencourt AMPure XP 
(Beckman Coulter) then oxidated with 1 µL of a KRuO4 (Alpha Aeser) solution (375 
mM in 0.3 M NaOH), after which bisulfite conversion was performed using EpiTect 
bisulfite kit (Qiagen®).  
After PCR amplification of the region of interest in oxBS and BS samples, 
pyrosequencing was performed using PyroMark Q24 reagents, and vacuum prep 
workstation, equipment and software (Qiagen®). To avoid negative methylation values 
due to the substraction of the oxBS and BS signals, 5mC and 5hmC estimations were 
calculated by means of a maximum likelihood model using the OxyBS R CRAN 
package (version 1.5) (50). Briefly, percentages of CpG methylation obtained from the 
PyroMark Q24 software were used as beta values for the BS or the oxBS treated 
samples, and signal intensities from the oxBS and BS experiments were obtained from 
the peak height signals of the corresponding nucleotides measured in the 
pyrosequencing reaction. 
 
Genome-wide DNA methylation analysis with high-density arrays 
Microarray-based DNA methylation profiling was performed with the 
HumanMethylation 450 BeadChip (51). Oxidative bisulfite (oxBS) and bisulfite-only 
(BS) conversion was performed using the TrueMethyl® protocol for 450K analysis 
(Version 1.1, CEGX) following the manufacturer’s recommended procedures. 
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Processed DNA samples were then hybridized to the BeadChip (Illumina), following 
the Illumina Infinium HD Methylation Protocol. Genotyping services were provided by 
the Spanish Centro Nacional de Genotipado (CEGEN-ISCIII) (www.cegen.org). Array 
data were deposited in ArrayExpress accession numbers E-MTAB-6003. 
 
HumanMethylation450 BeadChip data preprocessing 
Raw IDAT files were processed using the R/Bioconductor package minfi (52) (version 
1.14.0), implementing the SWAN algorithm (53) to correct for differences in the 
microarray probe designs. No background correction or control probe normalization 
was applied. Probes where at least two samples had detection p-values > 0.01, and 
samples where at least 5500 probes had detection p-values > 0.01 were filtered out. M-
values and beta values were computed as the final step in the preprocessing procedure. 
In line with a previously published methodology (54), M-values were used for the 
statistical analyses and beta values for effect size thresholding, visualization and report 
generation. 
 
Batch effect correction 
In order to detect whether there was any batch effect associated with technical factors, 
the visualization technique of multidimensional scaling (MDS) was employed to 
highlight any strange interaction affecting the different samples. Where necessary, 
posterior adjustment of the samples was performed by means of the SVA method (55) 
implemented in the R/Bioconductor sva package (version 3.14.0). 
 
Computation of hydroxymethylation levels 
Beta values from oxBS samples were subtracted from their corresponding BS treated 
pairs, generating an artificial dataset representing the level of 5hmC for each probe and 
sample as per a previously published methodology (56). One further dataset was created 
to represent the 5mC levels using beta values from oxBS samples.  
 
Detection of differentially methylated probes 
Differential methylation and hydroxymethylation of an individual probe was determined 
by a moderated t-test implemented in the R/Bioconductor package limma (57). A linear 
model, with methylation or hydroxymethylation levels as response and the sample 
group (normal/tumoral) as the principal covariate of interest, was then fitted to the 
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methylation or hydroxymethylation data. Surrogate Variables generated using SVA 
were also included in the model definition but excluding those found to be correlated to 
the phenotype of interest. P values were corrected for multiple testing using the 
Benjamini-Hochberg method for controlling false discovery rate (FDR). An FDR 
threshold of 0.001 was employed to determine differentially methylated and 
hydroxymethylated probes. Additionally, these probes were filtered according to their 
effect size, keeping only those probes with methylation or hydroxymethylation changes 
between-groups which exceeded the median of all differences for the same comparison. 
The probes without no significant 5hmC signal on control samples were filtered out 
from the set of hypo-hydroxymethylated probes in glioma. 
In order to describe the genomic distribution of 5hmC in brain, we used Hilbert curves 
(58), which are especially suited to the visualization of simple measurements, such as 
the location of the 5hmC enriched probes, over large scales. These curves allow for 
compact representation on a genomic scale and have an interesting property by which 
two points which are near each other in the one-dimensional genomic location space are 
also closely located in the two-dimensional transformation generated by the curve. The 
converse may not always be true. 
 
Identification of hydroxymethylated probes 
In order to identify those probes representing the regions where the 5hmC mark is 
located, a differential hydroxymethylation analys s was performed as described 
previously (59) using a dataset containing both oxBS and BS versions of the control 
samples. Probes with significant differences in beta values between the BS and oxBS 
samples were considered to be enriched for the 5hmC mark. An FDR threshold of 0.001 
was employed. No filtering on effect size was applied in this case. 
 
5-hydroxymethylcytosine immunoprecipitation-qPCR assay 
Immunoprecipitation of 5hmC was carried out using the EpiQuik Hydroxymethylated 
DNA Immunoprecipitation (hMeDIP) Kit (Epigentek), according to the manufacturer's 
instructions. 
Input, non-specific IgG- and 5hmC-enriched fractions were obtained from eleven 
samples corresponding to five normal brains, five glioma tumors and one glioma cell 
line. All these fractions were amplified by qPCR with oligonucleotides specific for the 
CpGs detailed in Supplementary Table 12. After confirming there were no significant 
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differences between input DNAs, 5hmC relative enrichment was calculated as a Fold 
Change relative to Input Ct Mean. 
 
Histone enrichment analysis 
In order to analyze the enrichment of histone marks on a subset of probes, we used the 
information contained in the UCSC Genome Browser Broad Histone tracks from the 
ENCODE Project (10 different cell types) and the NIH Roadmap Epigenome 
consortium (8 brain cell types, but less available ChIP-seq data). Histone mark peaks 
were downloaded for every combination of cell line and antibody. For each track, a 2x2 
contingency table was built to represent the partition of the whole set of possible probes 
in the microarray with respect to the membership of the subset of interest and the 
overlap between the probes and the histone peaks. A Fisher's exact test was used to 
determine whether there was significant enrichment of the selected histone mark for the 
subset of interest. P-values were adjusted for multiple comparisons using the 
Benjamini-Hochberg method for controlling FDR. A significance level of 0.05 was used 
to determine whether the given combination of histone mark and cell line presented a 
significant change in proportion. Additionally, the base-2 logarithm of the Odds Ratio 
(OR) was used as a measure of effect size. 
 
Chromatin segment enrichment analysis 
Data from the BROAD ChromHMM Project were downloaded from the UCSC Genome 
Browser and the NIH Roadmap Epigenome consortium. Each of the tracks comprising 
these datasets represents a different segmentation (15 and 18 chromatin states 
respectively) generated by a Hidden Markov Model (HMM) using Chip-Seq signals 
from the Broad Histone Project as inputs. The segmentations were later curated and 
labelled according to their functional status (60, 61). In order to detect any significant 
enrichment in the proportion of probes in a given subset of interest belonging to one 
functional category, an analysis strategy similar to the one employed for the detection of 
histone enrichment was performed. In this case, a 2x2 contingency table was built using 
segments of a given functional status rather than antibodies. A Fisher's exact test was 
employed, and significant combinations were detected using a FDR threshold of 0.05 
(Benjamini-Hochberg procedure). Again, the base-2 logarithm of the OR was used as a 
measure of effect size. 
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Genomic region analysis 
The probes in the microarray were assigned to a genomic region according to their 
position relative to the transcript information extracted from the R/Bioconductor 
package TxDb.Hsapiens.UCSC.hg19.knownGene (package version 3.1.2). A probe was 
said to be in a promoter region if it was located in a region up to 2kb upstream of the 
transcription start site (TSS) of any given transcript. Similarly, a set of mutually 
exclusive regions were defined inside the transcripts, namely 5UTR, 3UTR, First Exon, 
Exon and Intron. A probe could only belong to one category, hence if the location of a 
probe overlapped with two or more regions in different transcripts, it was assigned to 
the region with a higher level of precedence (i.e. in the order stated above, earlier 
mention indicates higher precedence). If a probe was not assigned to any of these 
special regions, it was labelled by default as Intergenic. A contingency table was built 
for each of the subsets, pa titioning the whole set of probes according to membership to 
a given category and the subset of interest. A Pearson's χ2 test was used to determine 
whether there was any significant change in proportion between the number of probes 
marked as belonging to a given region inside and outside the subset of interest. A 
significance level of 0.05 was employed, and effect size measured by OR. 
 
CGI status analysis 
Similar to the genomic region analysis, probes were labelled according to their relative 
position to CpG-islands (CGIs), the locations of which were obtained from the 
R/Bioconductor package FDb.InfiniumMethylation.hg19 (package version 2.2.0). The 
generation procedure of these CGIs is described by (62), i.e. ‘CpG shores’ were defined 
as the 2kbp regions flanking a CGI. ‘CpG shelves’ were defined as the 2kbp regions 
either upstream of or downstream from each CpG shore. Probes not belonging to any of 
the regions thus far mentioned were assigned to the special category ‘non-CGI’ with 
each probe being assigned to only one of the categories. A 4x2 contingency table was 
constructed for each subset of probes in order to study the association between the given 
subset and the different CGI categories. A χ2 test was used to determine whether any of 
the categories had a significant association with the given subset. For each of the CGI 
status levels, a 2x2 contingency table was defined and another χ2 test used to 
independently evaluate the association of the given subset with each status level, a 
significance level of 0.05 being employed for all tests. Effect size was reported as the 
OR for each of the individual tests. 
Page 18 of 37Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
 
Analysis of CpG density  
For each of the probes in the HumanMethylation450 microarray, CpG density was 
measured as the number of CG 2-mers present divided by the number which would be 
theoretically possible in a 2kbp window with the CpG under study at its centre. A 
Wilcoxon non-parametric test was used to determine if any significant difference 
existed between the CpG density of each subset of interest and that of the array probes 
in the background. A significance level of 0.05 was employed for all tests. Effect size 
was measured using Cliff's Delta (D). 
 
Gap distance analysis 
Distance to both the centromere and telomere was measured for each of the probes in 
the HumanMethylation450 microarray. In order to find significant differences between 
the probes within the subset of interest and those in the background, a Wilcoxon non-
parametric test was used. Once again, a significance level of 0.05 was employed for all 
tests, and Cliff's Delta (D) was used as a measure of effect size. 
 
Microarray background correction 
Although it is sometimes referred to as a genome-wide solution, the 
HumanMethylation450 BeadChip only covers a fraction of the entire genome. In its 
27K predecessor, the probes were mainly located at gene promoter regions, while the 
newer HumanMethylation450 BeadChip additionally includes probes located inside 
genes and in intergenic regions (63). 
The irregular distribution of probes can however lead to unwanted biases when studying 
whether a selected subset of probes is enriched with respect to any functional or clinical 
mark. For this reason, here a reference to the background distribution of features was 
included in all statistical tests performed in order to prevent our conclusions from being 
driven by the irregular distribution of probes. In qualitative tests (CGI status, genomic 
region, or histone mark enrichment), the contingency matrix was built to represent the 
background distribution of the microarray. In quantitative tests (CpG density, distance 
to centromeres and telomeres) the corresponding metric was compared between the 
subset of interest and the remaining probes in the microarray. Thus, any significant 
result would indicate a departure from the fixed background distribution and ignore any 
bias inherent in the test. 
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Gene ontology analysis and annotation 
Probe sets were converted to gene sets by using the annotation information from the 
R/Bioconductor package TxDb.Hsapiens.UCSC.hg19.knownGene (version 3.1.2). A 
probe was assigned to a gene if the probe was contained within the overlap of all the 
genomic regions represented by the different transcripts belonging to that gene, or in a 
2kbp region upstream of the corresponding TSS. Probes converted this way can be 
assigned to one or more genes, or to zero (i.e. intergenic probes). 
After gene conversion, each subset of interest was analyzed using the HOMER software 
tool (64). The software was configured to use the whole set of genes represented in the 
HumanMethylation450 architecture as a background. HOMER tested the genes in each 
subset of interest against 21 different databases, including the Gene Ontology (GO) 
Biological Process, Molecular Function and Cellular Component ontologies, as well as 
KEGG and Reactome pathway databases, among many others. 
 
Circular visualization and track smoothing 
In order to plot the CpG and histone peak information on the circular genome-wide and 
example graphs, smoothing was applied to the data. CpG enrichment information for 
canonical and non-canonical hypermethylation was generated by partitioning the 
genome into intervals of 10kbp and assigning to each a score corresponding to the 
average coverage of the selected CpGs in the interval. 
 
Whole-genome bisulfite sequencing (WGBS) datasets 
Tet-assisted bisulfite sequencing (TAB-Seq) data, corresponding to an adult brain 
prefrontal cortex tissue sample (GSM1135082) (29), was used as a validation dataset for 
the location of 5hmC in controls. 
Additionally, TrueMethyl (ox-BS) Whole Genome data referenced in (34) (E-MTAB-
5171), obtained from a single glioblastoma patient, was used as a validation dataset. 
Previously processed data in the form of quantified methylation for each CpG measured 
in both strands of the genome was downloaded and filtered. The resulting dataset 
comprised only two samples (normal and tumoral), hence a descriptive strategy was 
used to distinguish the different types of probe according to their methylation status.  
For both the TAB-Seq and TrueMethyl-seq validation datasets, hydroxymethylated 
probes were identified as those having a 5hmC measure higher than 0.1. In the case of 
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WGBS, differentially methylated probes were defined as those having an absolute 
difference in their methylation values between the control and tumor samples which was 
above a given threshold (0.2 for 5mC and 0.1 for 5hmC). Only methylation measures 
from CpGs having a total read count higher than 10 were retained. 
The validation datasets may contain either one or two methylation measures for each 
CpG in the genome as they measure methylation in both strands. Strand- agnostic CpG 
regions representing the CpG dinucleotides with at least one measure were defined in 
order to compute the degree of intersection between the WGBS and methylation arrays 
results. 
 
The Cancer Genome Atlas (TCGA) expression and methylation dataset  
In order to analyze changes in gene expression, samples of glioblastoma multiforme 
(GBM) were selected from among the data generated by the TCGA Research Network 
(http://cancergenome.nih.gov). DNA Methylation data for GBM was additionally 
obtained from TCGA for visualization and validation purposes. 
Expression Level-3 pre-processed data was obtained for 572 GBM samples (10 controls 
and 562 tumors). The moderated t-test approach in the R/Bioconductor package limma 
was used to assess the differential expression status of each gene in the TCGA datasets. 
The normalized expression ratio in the TCGA datasets was used as the response 
variable, and the sample group (normal/tumoral) as the covariate of interest. No 
adjustment for possible confounders was performed in this case. An FDR threshold of 
0.001 was used to correct for multiple hypotheses. No filtering on effect size was 
applied in this case. 
DNA Methylation Level-1 raw data for the Illumina 450k architecture was obtained for 
162 GBM samples (33). The raw values were normalized using the SWAN algorithm. 
No additional filtering was performed on the samples. 
 
Data analysis workflow 
All the necessary steps for upstream and downstream analyses were defined and 
implemented using the Snakemake tool (65), which helps data scientists to generate a 
reproducible and inherently parallel processing pipeline. Individual workflow tasks 
were implemented in R (version 3.2.2) and Python (version 3.4.3).  
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Figure legends 
 
Figure 1. 5mC and 5hmC levels at repetitive DNA sequences in glioma. 5mC (a) 
and 5hmC (b) values of several repetitive regions (AluYb8, LINE-1, NBL-2, and Sat-
alpha) measured by pyrosequencing in controls and gliomas. Individual CpG site values 
for each repeat are displayed, and a linear model including both “sample group” and 
“CpG site” as covariates was fitted. Significant p-values for any repetitive region are 
shown. 
 
Figure 2. Characterization of DNA 5hmC in normal brain. (a) Bean plots showing 
differences between average Beta values of 5mC+5hmC (BS) and true 5mC (OxBS) 
values in normal brain. The diamond inside the bean indicates the mean value. Hilbert 
curve showing the amount and genomic distribution of 5hmC in brain. A level-9 Hilbert 
curve was used. Each region delimited by black lines represents a chromosome. A point 
in the image represents a genomic segment of approximately 950bp. A blue point 
indicates presence of at least one 5hmC enriched CpG in the given segment. A Hilbert 
curve including all CpG sites analyzed in the methylation array (450K) is also shown 
(b) Associations between 5hmC and CpG density. (c) Distribution of 5hmC CpG sites 
relative to CpG island status and compared to the array background (450K). (d) 
Distribution of 5hmC CpG sites relative to different genomic regions. (e) Heatmaps 
showing significant enrichment of the 5hmC CpG sites identified in brain, with different 
histone marks contained in the UCSC Browser Broad Histone track from the ENCODE 
project. Color code indicates the significant enrichment based on log2 odds ratio (OR). 
(f) Heatmaps showing significant enrichment of 5hmC CpG sites with fifteen 
“chromatin states” generated by a Hidden Markov Model (HMM). Color codes indicate 
the significant enrichment based on log2 odds ratio (OR). 
 
Figure 3. Alterations of 5hmC in glioma. (a) Bar plot showing the number of d5hmC 
sites in glioma. (b) Unsupervised hierarchical clustering and heatmap including CpG 
sites with 5hmC loss in glioma (3,000 random probes). (c) Associations between 5hmC 
loss in glioma and density of CpGs (upper panel), CpG island status (middle panel), and 
different genomic regions (lower panel). (d) Heatmaps showing significant enrichment 
of hypo 5hmC CpGs identified in glioma with different histone marks contained in the 
UCSC Browser Broad Histone track from the ENCODE project. (e) Heatmaps showing 
significant enrichment of hypo 5hmC CpGs in gliomas with fifteen “chromatin states” 
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generated by a Hidden Markov Model (HMM) (right panel). Color codes indicate the 
significant enrichment based on log2 odds ratio (OR). 
 
Figure 4. Relationships between changes in 5mc and 5hmc in glioma. (a) Euler 
diagram illustrating overlap of CpGs that lose 5hmC (hypo 5hmC) and gain 5mC (hyper 
5mC) in glioma. (b) Associations between hypermethylated CpG sites that lose (or not) 
5hmC and CpG density (upper panel) and CpG island status (lower panel), compared to 
the array background (450K). (c) Unsupervised hierarchical clustering and heatmap 
including 3000 randomly chosen CpG sites with 5mC changes (hyper- and 
hypomethylation) in glioma. Hypo- (purple) and non-hypo (orange) 5hmC overlapped 
CpGs are indicated by colored lines on the annexed track. Average beta methylation 
values are displayed fr m 0 (blue) to 1 (yellow). 
 
Figure 5. Canonical and non-canonical hypermethylation in glioma. (a) Heatmaps 
showing significant enrichment of CpG sites in glioma which exclusively gain 5mC 
(canonical hypermethylation) (upper panel), and both lose 5hmC and gain 5mC (non-
canonical hypermethylation) (lower panel), with different histone marks contained in 
the UCSC Browser Broad Histone track from the ENCODE project. Histone PTMs 
related to activation and repression are distinguished by colors as indicated in the key. 
(b) Circular representation of two representative chromosomes (12 and 17), indicating 
genomic location of canonical (orange) and non-canonical (purple) hypermethylation in 
glioma. Inner tracks display chromatin marks (H3K9me3, H3K27me3, and H3K4me2), 
generated for NH-A cells. Two examples of genes showing canonical and non-canonical 
hypermethylation associated with specific chromatin signatures are displayed below. 
 
Figure 6. Functional role of canonical and non-canonical hypermethylation in 
glioma. (a) Euler diagrams showing number of genes associated with canonical 
hypermethylation, non-canonical hypermethylation, or both.  On the right are 
representative gene ontology terms (Biological process) of genes associated with 
canonical (orange) and non-canonical (purple) hypermethylation, ranked by Q-value, 
and enrichment score (relative risk). (b) Euler diagram showing overlap of canonical 
and non-canonical hypermethylated genes with down-regulation. (c) Associations of 
canonical and non-canonical hypermethylation in glioma with different genomic 
regions. (d) Representative example of one gene (SLC1A4) showing non-canonical 
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hypermethylation in glioma (orange frame). Organization of the gene, locations of 
CpGs included in the methylation array (black dots), and transcription start site (TSS) 
are shown below. 5mC hypermethylation (blue to yellow) and 5hmC loss (gray to blue) 
in glioma are shown above. Whole genome bisulfite sequencing (WGBS) data (34) 
including all the CpG sites in the same region are shown on the right. The associated 
change in gene expression is displayed below. 
 
Figure 7. Schematic representation of genomic regions and related histone marks 
associated with canonical and non-canonical DNA hypermethylation in glioma. 
CpG sites that suffered canonical hypermethylation are overrepresented in CpG islands 
(CGI) and in poised promoters and repressed regions enriched in H3K27me3 and 
H3K9me3. In contrast, non-canonical hypermethylated CpG sites are enriched in CGI 
shores, and enhancers and transcribed regions characterized for activating histone 
marks. 
Abbreviations 
 
5hmC: 5-hydroxymethylcytosine 
5mC: 5-methylcytosine 
CGI: CpG island 
TET1, TET2, and TET3: ten-eleven translocation proteins 1, 2, and 3 
TAB-Seq: Tet-Assisted Bisulfite Sequencing 
OR: Odd ratio 
ChIP-seq: Chromatin Immunoprecipitation Sequencing 
d5hmC: differentially hydroxymethylated CpG sites 
hMeDIP: hydroxymethylated DNA Immunoprecipitation 
PTMs: Post-translational modifications 
TCGA: The Cancer Genome Atlas 
WGBS: whole-genome bisulfite sequencing 
GO: Gene ontology 
c-DMRs: differentially methylated regions 
oxBS: oxidative bisulfite conversion 
BS: bisulfite conversion 
SWAN: Subset-quantile Within Array Normalization 
MDS: multidimensional scaling 
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SVA: Surrogate variable analysis 
FDR: false discovery rate 
GBM: glioblastoma 
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